3ST-POL trial: Standards of statin use in Poland in the context of the European Society of Cardiology guidelines

Polskie Archiwum Medycyny Wewnetrznej

Volumn 120, Issue 9, 2010, Pages 328-333

  Śliz, Daniel ^a   Mamcarz, Artur ^a   Filipiak, Krzysztof J ^a   Siebert, Janusz ^b   Naruszewicz, Marek ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Atherosclerosis; Dyslipidemia; Hyperlipemia; Ischemic heart disease; Pharmacoeconomics

Indexed keywords

ATORVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; ANTIHYPERTENSIVE AGENT; HYPOCHOLESTEROLEMIC AGENT;

ADULT; AMBULATORY CARE; ARTICLE; BLOOD PRESSURE; CARDIOLOGY; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OBESITY; PHYSICAL EXAMINATION; PHYSICIAN; POLAND; PRACTICE GUIDELINE; QUESTIONNAIRE; SMOKING; STROKE; TRANSIENT ISCHEMIC ATTACK; AGED; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; COMORBIDITY; ECONOMICS; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; ORGANIZATION AND MANAGEMENT; PRIMARY PREVENTION; SECONDARY PREVENTION; STATISTICS;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OBESITY; PHYSICIAN'S PRACTICE PATTERNS; POLAND; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; SECONDARY PREVENTION; SMOKING; STROKE;

EID: 79952118483     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.959     Document Type: Article

References (15)

1. HeartScore. http://www.heartscore.org/eu/Pages/Welcome.aspx Accessed February 15, 2010.
2. Ridker PM; JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation. 2003; 108: 2292-2297.
3. Śliz D, Filipiak KJ, Naruszewicz M, et al. [Ambulatory pharmacological treatment of hypertension in the context of ESC/ESH/PTNT in general population and in patients with type 2 diabetes. 3ST-POL study]. Kardioprofil. 2009; 3; 191-198. Polish.
4. WHO. http://www.who.int/whr/2002/chapter4/en/index4.html. Accessed February 15, 2010.
5. Baigent C, Keech A, Kearney PM, et al.; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366: 1267-1278.
6. Tolonen H, Keil U, Ferrario M, Evans A; WHO MONICA Project. Prevalence, awareness and treatment of hypercholesterolaemia in 32 populations: results from the WHO MONICA Project. Int J Epidemiol. 2005; 34: 181-192. (Pubitemid 40347392)
7. Kawecka-Jaszcz K, Paja̧k A, Jankowski P. [Cracovian Program for Secondary Prevention of Ischaemic Heart Disease]. Przegl Lek. 2001; 58: 953-955. Polish.
8. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet. 2001; 357: 995-1001.
9. Phatak H, Wentworth C, Sazanov V, Bruke T. Prevalence and predictors of lipid abnormalities in patients treated with statin In UK general practice. Atherosclerosis. 2009; 202: 225-233.
10. Pietrasik A, Starczewska M, Główczyńska R, et al. Secondary prevention of myocardial infarction in primary care - selected results of POLKARD-SPOK study. Kardiol Pol. 2006; 64: 210-217.
11. Cooney MT, Dudina A, De Bacquer D, et al; SCORE investigators. HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk. Atherosclerosis. 2009; 206: 611-616.
12. Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol. 1997; 80: 106-107.
13. Cannon CP, Braunwald E, McCabe CH, et al.; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350: 1495-1504.
14. LaRosa JC, Grundy SM, Waters DD, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352: 1425-1435. (Pubitemid 40471450)
15. Yusuf S, Pais P, Afzal R, et al.; Indian Polycap Study (TIPS). Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet. 2009; 373: 1341-1351.